Bayesian methods in cost-effectiveness studies: Objectivity, computation and other relevant aspects

Health Economics

Volumn 19, Issue 6, 2010, Pages 629-643

  Armero, C ^a   Garcia Donato G ^b   Lopez Quilez A ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Cost effectiveness studies; Objective Bayesian methods; Probabilistic sensitivity analysis

Indexed keywords

ARTICLE; BAYES THEOREM; COST EFFECTIVENESS ANALYSIS; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BAYES THEOREM; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; MARKOV CHAINS; MONTE CARLO METHOD; OSTEOARTHRITIS;

EID: 77952786842     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1496     Document Type: Article

References (67)

1. Ades AE, Claxton K, Sculpher M. 2006. Evidence synthesis, parameter correlation and sensitivity analysis. Health Economics 15: 373-381.
2. Baldi F, Bianchi Porro G, Dobrilla G et al. 1988. Cisapride versus placebo in reflux esophagitis: a multicenter double-blind trial. Journal of Clinical Gastroenterology 10: 614-618. (Pubitemid 19008984)
3. Bayarri MJ, Berger JO. 2004. The interplay between Bayesian and frequentist analysis. Statistical Science 19: 58-80.
4. Bayarri MJ, Berger JO, Cafeo J et al. 2007. Computer model validation with functional output. Annals of Statistics 35: 1874-1906.
5. Bayarri MJ, García-Donato G. 2007. Extending conventional priors for testing general hypotheses in linear models. Biometrika 94: 135-152. (Pubitemid 46410723)
6. Berger JO. 2006. The case for objective Bayesian analysis. Bayesian Analysis 1: 385-401.
7. Berger JO, Bernardo JM. 1992. On the development of the reference prior method. In Bayesian Statistics, Bernardo JM, Berger JO, Dawid AP, Smith AFM (eds), vol. 4. Oxford University Press: Oxford; 35-60.
8. Berger JO, Deely J. 1988. A Bayesian approach to ranking and selection of related means with alternatives to analysis-of-variance methodology. Journal of the American Statistical Association 83: 364-373.
9. Berger JO, Pericchi RL. 2001. Objective Bayesian methods for model selection: introduction and comparison (with Discussion). In Model Selection, Lahiri P (ed.). Institute of Mathematical Statistics: Beachwood, OH; 135-207.
10. Berger JO, Strawderman WE. 1996. Choice of hierarchical priors: admissibility in estimation of normal means. Annals of Statistics 24: 931-951. (Pubitemid 126131262)
11. Berger ML, Bingefors K, Hedblom E, Pashos CL, Torrance G (eds). 2003. Health Care Cost, Quality and Outcomes: ISPOR Book of Terms. International Society for Pharmoeconomics and Outcomes Research: Lawrenceville, NJ.
12. Bernardo JM. 1979. Reference posterior distributions for Bayesian inference (with Discussion). Journal of the Royal Statistical Society, Series B 41: 113-147.
13. Biggerstaff BJ, Tweedie RL. 1997. Incorporating variability in estimates of heterogeneity in the random effects model in meta analysis. Statistics in Medicine 16: 753-768.
14. Briggs AH. 2000. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17: 479-500.
15. Briggs AH, Goeree R, Blackhouse G, OBrien BJ. 2002. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making 22: 290-308. (Pubitemid 34791317)
16. Briggs A, Sculpher M. 1998. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13: 397-409. (Pubitemid 28140699)
17. Brown J, Welton NJ, Bankhead C et al. 2006. A Bayesian approach to analysing the cost-effectiveness of two primary care interventions aimed at improving attendance for breast screening. Health Economics 15: 435-445.
18. Casella G, Berger R. 2001. Statistical Inference (2nd edn). Brooks/Cole: Pacific Grove, CA.
19. Chen MH, Shao QM, Ibrahim JG. 2000. Monte Carlo Methods in Bayesian Computation. Springer: Berlin.
20. Christen JA. 2006. Stop using 'subjective' to refer to Bayesian analyses (comment on articles by Berger and by Goldstein). Bayesian Analysis 1: 421-422.
21. Craig BA, Fryback DG, Klein R, Klein BEK. 1999. A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. Statistics in Medicine 18: 1355-1371. (Pubitemid 29261494)
22. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. 1997. Primer on medical decision analysis: part 2 - building a tree. Medical Decision Making 17: 126-135. (Pubitemid 27157027)
23. Draper D. 2006. Coherence and calibration: comments on subjectivity and 'objectivity' in Bayesian analysis (comment on articles by Berger and by Goldstein). Bayesian Analysis 1: 423-428.
24. Fienberg SE. 2006. Does it make sense to be an 'objective Bayesian'? (comment on Articles by Berger and by Goldstein). Bayesian Analysis 1: 429-432.
25. Galmiche JP, Fraitag B, Filoche B et al. 1990. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Digestive Diseases and Sciences 35: 649-655. (Pubitemid 20172972)
26. Gamerman D, Lopes HF. 2006. Monte Carlo Markov Chain: Stochastic Simulation for Bayesian Inference (2nd edn). Chapman & Hall: London.
27. Geldof H, Hazelhoff B, Otten MH. 1993. Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a doubleblind comparison with ranitidine. Alimentary Pharmacology & Therapeutics 7: 409-415. (Pubitemid 23267017)
28. Gilks WR, Best NG, Tan KKC. 1995. Adaptive rejection Metropolis sampling within Gibbs sampling. Applied Statistics 44: 455-472.
29. Goeree R, OBrien B, Hunt R et al. 1999. Economic evaluation of long term management strategies for erosive oesophagitis. Pharmacoeconomics 16: 679-697. (Pubitemid 30002436)
30. Gold MR, Siegel JE, Russell LB, Weinstein MC. 1996. Cost- effectiveness in Health and Medicine. Oxford University Press: Oxford.
31. Goldstein M. 2006. Subjective Bayesian analysis: principles and practice. Bayesian Analysis 1: 403-420.
32. Hazen GB. 2000. Preference factoring for stochastic trees. Management Science 46: 389-403.
33. Hazen GB, Pellissier JM, Sounderpandian J. 1998. Stochastic tree models in medical decision making. Interfaces 28: 64-80. (Pubitemid 128137197)
34. Hollenberg JP. 1984. Markov cycle trees: a new representation for complex Markov processes (abstract). Medical Decision Making 4: 529.
35. Ibrahim JG, Chen MH, Sinha D. 2001. Bayesian Survival Analysis. Springer: Berlin.
36. Kadane JB. 2006. Is 'objective Bayesian analysis' objective, Bayesian, or wise? (comment on Articles by Berger and by Goldstein). Bayesian Analysis 1: 433-436.
37. Kamath CC, Kremers HM, Vaness DJ et al. 2003. The cost-effectiveness of acetaminophen, NSAIDs and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value in Health 6: 144-157.
38. Kass RE. 2006. Kinds of Bayesians (comment on Articles by Berger and by Goldstein). Bayesian Analysis 1: 437-440.
39. Kass RE, Wasserman L. 1996. The selection of prior distributions by formal rules. Journal of the American Statistical Association 91: 1343-1369.
40. Kullback S. 1968. Information Theory and Statistics. Dover Publications: New York.
41. Lad F. 2006. Objective Bayesian statistics. Do you buy it? Should we sell it? (comment on Articles by Berger and by Goldstein). Bayesian Analysis 1: 441-444.
42. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. 2005. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Statistics in Medicine 24: 2401-2428.
43. Lee PM. 1997. Bayesian Statistics. An Introduction (2nd edn). Arnold: London.
44. Lepoutre L, Van Der Spek P, Vanderlinden I et al. 1990. Healing of grade-II and III oesophagitis through motility stimulation with cisapride. Digestion 45: 109-114. (Pubitemid 20151609)
45. Maetzel A, Krahn M, Naglie G. 2003. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and Rheumatism 49: 283-292. (Pubitemid 36682393)
46. Maleev A, Mendizova A, Popov P et al. 1990. Cisapride and cimetidine in the treatment of erosive esophagitis. Hepatogastroenterology 37: 403-407. (Pubitemid 20298894)
47. Negrín MA, Vázquez-Polo J. 2006. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability curve. Health Economics 15: 363-372.
48. O'Hagan A. 2006. Science, subjectivity and software (comment on Articles by Berger and by Goldstein). Bayesian Analysis 1: 445-450.
49. O'Hagan A, Stevens JW. 2001. Bayesian assessment of sample size for clinical trials of cost-effectiveness. Medical Decision Making 21: 219-230. (Pubitemid 32452766)
50. O'Hagan A, Stevens JW, Montmartin J. 2000. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 17: 339-349. (Pubitemid 30236169)
51. O'Hagan A, Stevens JW, Montmartin J. 2001. Bayesian cost-effectiveness analysis from clinical trial data. Statistics in Medicine 20: 733-753. (Pubitemid 32177846)
52. Parmigiani G. 2002. Modeling in Medical Decision Making. A Bayesian Approach. Wiley: New York.
53. R Development Core Team. 2006. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria. ISBN 3-900051-07-0. Available from: http://www.R-project.org.
54. Richter JE, Long JF. 1995. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. American Journal of Gastroenterology 90: 423-430.
55. Robertson CS, Evans DF, Ledingham SJ et al. 1993. Cisapride in the treatment of gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics 7: 181-190. (Pubitemid 23109465)
56. Rothschild BM. 1996. Cost savings and prescribing protocols for nonsteroidal anti-inflammatory drugs. Journal of the American Medical Association 276: 525-526. (Pubitemid 26272292)
57. Silverstein FE, Faich G, Goldstein JL et al. 2000. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. Journal of the American Medical Association 284: 1247-1255.
58. Sonnenber FA, Beck JR. 1993. Markov models in medical decision making. A practical guide. Medical Decision Making 13: 322-338.
59. Spiegelhalter DJ, Best NG. 2003. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Statistics in Medicine 23: 3687-3709.
60. Spiegelhalter DJ, Thomas A, Best N, Lunn D. 2001. WinBUGS User Manual: Version 1.4. MRC Biostatistics Unit: Cambridge, UK.
61. Sun D. 1997. A note on noninformative priors for Weibull distributions. Journal of Statistical Planning and Inference 61: 319-338.
62. Tanner MA. 1991. Tools for Statistical Inference. Springer: Berlin.
63. Wasserman L. 2006. Frequentist Bayes is objective (comment on articles by Berger and by Goldstein). Bayesian Analysis 1: 451-456.
64. Weinstein MC, O'Brien B, Hornberger J et al. 2003. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices - modeling studies. Value in Health 6: 9-17. (Pubitemid 36228345)
65. Welton NJ, Ades AE. 2005. Estimation of Markov chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis and model calibration. Medical Decision Making 25: 633-645.
66. Yang R, Berger JO. 1996. A catalog of noninformative priors. ISDS Discussion Paper, Duke University.
67. Ye K. 1993. Sensitivity study of the reference priors in a random effect model. Technical Report, Department of Statistics, Virginia Polytechnic Institute and State University.